— REDUCE 1 is a study running in parallel with REDUCE 2 to evaluate AR882's efficacy in lowering serum urate (sUA) levels in gout patients — SAN DIEGO , March 17, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced that it has dosed the first patient in REDUCE 1, the Company's second pivotal Phase 3 clinical trial evaluating AR882. "We are pleased to have enrolled the first patient in our REDUCE 1 study, our second confirmatory Phase 3 trial evaluating AR882's potential as a best-in-class treatment," said Litain Yeh, Ph.
D., Founder and CEO of Arthrosi Therapeutics. "This milestone, together with the rapid completion of enrollment in our Phase 3 REDUCE 2 study, continues to build momentum as we progress towards a New Drug Application for AR882 and deliver a much-needed treatment option that could significantly improve patient outcomes.
" REDUCE 1 is the Company's second pivotal twelve-month, randomized, double-blind, placebo-controlled study evaluating AR882. The study is expected to enroll up to 750 patients with gout who are inadequate responders to urate lowering therapies (ULTs) and ULT naïve. Patients will be randomized into one of three groups either receiving AR882 50 mg, AR882 75mg or placebo.
All patients will receive.